Arthritis

Question 1

NSAIDs MOA and adverse reactions

Answer 1

MOA: COX 1 and 2 inhibition

AR: GI ulceration, bleeding

Question 2

Corticosteroids MOA and adverse reactions

Answer 2

MOA: generalized immunosuppression, reduce proinflammatory cytokine production

AR: fluid retention, hyperglycemia, weight gain, osteoporosis and fx’s

Question 3

Hydroxychloroquine - Type of DMARD, MOA and adverse reactions

Answer 3

Traditional DMARD

MOA: not well understood, may be immunomodulation

AR: retinal damage, rash

Question 4

Methotrexate - Type of DMARD, MOA and adverse reactions

Answer 4

Traditional DMARD

MOA: reduces nucleotide synthesis

AR: hepatic fibrosis, rash, thrombocytopenia, leukopenia

Question 5

Leflunomide - Type of DMARD, MOA and adverse reactions

Answer 5

Traditional DMARD

MOA: inhibits pyrimidine synthesis

AR: hepatitis

Question 6

Sulfasalazine - Type of DMARD, MOA and adverse reactions

Answer 6

Traditional DMARD

MOA: not well understood

AR: rash, photosensitivity

Question 7

Etanercept - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 7

Biologic, TNF-alpha blocker

MOA: TNF-alpha inhibitor

AR: local-injection site

Question 8

Infliximab - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 8

Biologic, TNF-alpha blocker

MOA: chimeric monoclonal antibody targeted against TNF-alpha

AR: immune rxns, infection, malignancy

Question 9

Adalimumab - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 9

Biologic, TNF-alpha blocker

MOA: human antibody to TNF-alpha

AR: local injection site rxn, infection, malignancy

Question 10

Certolizumab - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 10

Biologic, TNF-alpha blocker

MOA: humanized antibody for human TNF-alpha

AR: local injection site rxn, infection, malignancy

Question 11

Golimumab - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 11

Biologic, TNF-alpha blocker

MOA: human antibody to TNF-alpha

AR: local injection site rxn, infection, malignancy

Question 12

Rituximab - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 12

Biologic, Non-TNF-alpha

MOA: depletes peripheral B cells by binding to CD20 cells and T cells

AR: immune rxns, infection, malignancy

Question 13

Abatacept - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 13

Biologic, Non-TNF-alpha

MOA: inhibits interaction btwn antigen-presenting cells and T cells

AR: immune rxn, infection, malignancy

Question 14

Tocilizumab - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 14

Biologic, Non-TNF-alpha

MOA: blocks interleukin-6 (IL-6) receptor

AR: local injection site rxns, infection, malignancy, GI perforation, neutropenia, thrombocytopenia

Question 15

Baricitinib - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 15

Biologic, Non-TNF-alpha

MOA: janus kinase (JAK) inhibitor

AR: infection, malignancy, hepatotoxicity, anemia, gastrointestinal perforations, thrombocytosis, neutropenia, increase in SCr and CPK

Question 16

Anakinra - Type of DMARD, TNF-alpha or not, MOA and adverse reactions

Answer 16

Biologic, Non-TNF-alpha

MOA: interleukin-1 (IL-1) receptor antagonist

AR: local injection site rxns, infection, malignancy